WG
XERS icon

Winton Group’s Xeris Biopharma Holdings XERS Stock Holding History

Winton Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Sell
20,787
-83,453
-80% -$533K 0.01% 1031
2026
Q1 		$605K Buy
104,240
+39,643
+61% +$263K 0.02% 660
2025
Q4 		$507K Sell
64,597
-26,196
-29% -$206K 0.02% 633
2025
Q3 		$739K Buy
+90,793
New +$603K 0.03% 516

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Winton Group's XERS Position: Q2 2026 in Review

Winton Group reduced its Xeris Biopharma Holdings (XERS) stake by 80% in Q2 2026, selling an estimated $533K and leaving 20,787 shares worth $165K. The position accounts for 0.01% of the portfolio, ranked #1031.

Winton Group first reported a position in XERS in Q3 2025 and has held it in 4 quarters since. The position peaked at $739K in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Winton Group held 20,787 shares of Xeris Biopharma Holdings worth $165K as of Q2 2026.
  • Winton Group sold 83,453 Xeris Biopharma Holdings shares in Q2 2026, an estimated $533K.
  • Xeris Biopharma Holdings made up 0.01% of Winton Group's portfolio in Q2 2026, its #1031 holding.
  • Winton Group first reported a position in Xeris Biopharma Holdings in Q3 2025 and has held it in 4 quarters since.
  • Winton Group's Xeris Biopharma Holdings position peaked at $739K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.